Cellectis S.A. (ALCLS.PA) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ALCLS.PA in your mock portfolio yet.
Negative EPS and a negative PE ratio indicate that Cellectis S.A. remains loss‑making, with no clear line of sight to near‑term profitability implied by the data provided. The current valuation is therefore not supported by earnings, and the equity story is still largely speculative and dependent on future execution rather than current financial strength.
The stock has gained 16.6% over the last month, signaling short‑term positive momentum. However, the current price of €2.94 remains below the 200‑day moving average of €3.23, which suggests the longer‑term trend is still downward or weak, tempering the recent bounce.
Hiring and social media metrics appear stagnant, indicating limited visible growth in operational scale or investor/consumer engagement. The flat job openings and essentially unchanged or slightly declining follower counts point to a lack of strong external momentum signals that might otherwise support a more optimistic outlook.
Overall, the combination of ongoing losses, a stock price still below its long‑term moving average, and muted alternative data signals points to a bearish stance on Cellectis S.A. While the recent 16.6% price rise shows some short‑term optimism, it is not yet corroborated by improving profitability or clear signs of accelerating business momentum.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started